BABiree Andemariam

Biree Andemariam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Biree Andemariam has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration

    by Hanny Al-Samkari, Fouzia Aboobacker, Biree Andemariam, Perla Eleftheriou, Hatoon Ezzat, Dimitrios Farmakis, Shahrukh Hashmi, Shruti Kakkar, Aurelio Maggio, Antonio Piga, et al.


  • Open Access

    Motivators and Barriers Affecting Decisions to Participate in Clinical Trials for Sickle Cell Disease: United States Findings from the Quantitative LISTEN Survey

    by Biree Andemariam, Adam Wufsus, Erik Hecht, Jeffrey R. Shearstone, Cassandra Trimnell

    Sickle cell disease (SCD) is an inherited blood disorder that results in abnormal hemoglobin and crescent-shaped red blood cells. While SCD was discovered over a century ago, it has historically had fewer new drugs in development compared with other conditions, negatively impacting patients’ therapeutic options. Recently, there has been a substantial increase in the development of novel therapies for SCD, but the perception that people with SCD (PwSCD) are hesitant to participate in clinical trials remains pervasive. Enhancing our understanding of factors that influence the participation of PwSCD in clinical trials is critical to ensuring trial completion, thereby supporting the development of new treatments. The Learnings and Insights into Sickle Cell Trial Experiences (LISTEN) Survey was a global, mixed methods study where PwSCD and health care professionals (HCPs) were surveyed about the importance of specific factors such as impact on daily life, treatment impact, and wider clinical trial outcomes, as well as basic trial information and further considerations, when deciding to participate in a trial. PwSCD were surveyed about their personal perspectives whereas HCPs were surveyed about their perceptions of patient perspectives towards these factors and channels. In the United States, we identified areas of disconnect between the perspectives of PwSCD and HCPs. Additionally, geographic region, education, income, sex, disease severity, and trial experience contextualized PwSCD responses and provided additional insights. Results from this survey may guide the design of future clinical trials and strengthen how HCPs and trial sponsors communicate with PwSCD, thereby reducing trial participation barriers.

  • Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease

    by Khaled M. Musallam, Biree Andemariam

    Inherited disorders of hemoglobin, including thalassemia and sickle cell disease (SCD), are among the most common monogenic diseases worldwide. They are no longer confined to the region extending f...

  • Open Access

    Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries

    by Biree Andemariam, Nirmish Shah, William B. Ershler, Edward Donnell Ivy, Deepika S. Darbari, Alan Anderson, Parul Rai, Ted Wun, Ching-Ray Yu, David M. Purdie, et al.

    Two registry studies, RETRO and PROSPECT, were conducted to evaluate real-world safety and effectiveness outcomes in US participants with sickle cell disease (SCD) who received voxelotor as standard of care. RETRO collected retrospective data of participants aged ≥12 years at 9 US sites for ∼1 year after voxelotor initiation. PROSPECT collected retrospective and prospective data of participants aged ≥4 years at 24 US sites, with a 5-year follow-up planned. Both studies collected data for 1 year before voxelotor initiation. RETRO enrolled 216 participants. PROSPECT enrolled 265 participants before voxelotor was withdrawn from global markets in September 2024; of these, 260 participants received voxelotor. The mean ± standard deviation (SD) voxelotor treatment duration was 50.52 ± 25.1 and 143.2 ± 65.6 weeks in RETRO and PROSPECT, respectively. Safety analyses included all participants who received voxelotor. The mean ± SD observed change in hemoglobin from baseline was from 0.6 ± 1.6 to 0.8 ± 1.5 g/dL in RETRO (∼1 year) and from 0.1 ± 1.7 to 0.7 ± 1.5 g/dL in PROSPECT (54 months). After starting voxelotor, decreases were observed from baseline in hemolysis markers (absolute/percentage reticulocyte counts, total/indirect bilirubin) across all RETRO time points and most PROSPECT time points. Acute pain crisis (APC) was the most common SCD complication (annualized incidence rates before and after voxelotor, respectively: RETRO: 1.33 and 1.54; PROSPECT 4.78 and 3.15). No new safety findings were identified. Despite inherent limitations of registry studies, voxelotor treatment increased hemoglobin and decreased hemolysis markers in US clinical practice, with no evidence of increased frequency of APC. These studies were registered at www.ClinicalTrials.gov as NCT04930328 and NCT04930445.


  • Open Access

    Sickle Cell Disease Burden in Sub-Saharan Africa Compared to Other Regions: Results from the SWAY Survey

    by Baba Inusa, Biree Andemariam, Caterina Minniti, Fuad El Rassi, Cassandra Trimnell, Miguel R. Abboud, Jean-Benoît Arlet, Raffaella Colombatti, Mariane de Montalembert, Suman Jain, et al.

  • Open Access

    Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US

    by Chuka Udeze, Michelle Jerry, Kristin Evans, Nanxin Li, Siddharth Jain, Biree Andemariam

    Aim: To describe real-world adherence, treatment utilization, vaso-occlusive crises (VOC) and economic outcomes in patients with sickle cell disease (SCD) with recurrent VOC treated with L-glutamine, voxelotor or crizanlizumab in the US. Materials & methods: In this retrospective study, patients with SCD with recurrent VOC who received L-glutamine, voxelotor, or crizanlizumab were identified from the Merative™ MarketScan ® Research Databases between 1 January 2015 and 30 September 2022. Eligible patients had ≥12 months continuous enrollment before and after the first chronic therapy claim (i.e., index date). Number of VOC, treatment utilization, healthcare resource utilization and healthcare costs were summarized for 12 months before (baseline) and after (follow-up) the index date. The proportion of days covered (PDC; i.e., proxy for adherence) for the index chronic therapy was measured during the 12-month follow-up period. Results: Overall, 440 patients initiated a recently approved chronic therapy (L-glutamine, n = 254; voxelotor, n = 110; crizanlizumab, n = 76) and met inclusion criteria. Mean (standard deviation [SD]) number of VOC during baseline and follow-up were similar for patients treated with any index therapy (n = 440; 7.21 [8.82] vs 7.27 [9.85]); this was similar across patients treated with L-glutamine, crizanlizumab, and voxelotor, respectively. Mean (SD) PDC for patients with any index therapy was 0.37 (0.29); results were similar across patients treated with L-glutamine, crizanlizumab, and voxelotor. Healthcare resource utilization during the 12-month baseline and follow-up periods were comparable. Mean (SD) total costs for patients initiating a recently approved chronic therapy increased by ∼50% or $38,111 during follow-up (follow-up, $118,235 [$177,125]; baseline, $80,125 [$120,950]; p < 0.001); most of the increased costs ($27,108 [71.1%]) were a direct result of recently approved chronic therapies. Conclusion: Patients initiated on L-glutamine, voxelotor or crizanlizumab had low adherence (based on PDC), continued to experience frequent VOC, and incurred higher healthcare costs mostly due to the costs of these therapies. This highlights the need for additional treatment options for patients with SCD with recurrent VOC.


  • Open Access

    The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) Trial: Protocol for a Randomized Controlled Trial

    by Tanisha D Belton, Caren M Steinway, Olivia Teng, Justine Shults, Lamia P Barakat, Banu Aygun, Abena Appiah-Kubi, Lori E Crosby, Omar Niss, Biree Andemariam, et al.

    Background: Transitioning from pediatric to adult sickle cell disease (SCD) care is challenging for emerging adults (aged 17-25 years). This period is marked by a 7-fold increase in mortality rates and has the highest rates of hospitalizations, emergency room visits, and hospital readmissions compared with children living with SCD. These challenges are exacerbated by fragmented care coordination, difficulty navigating adult health care systems, and increased self-management responsibilities. Objective: This study aims to compare the effectiveness of 2 interventions designed to support emerging adults living with SCD during this transition: a mobile health (mHealth) app and community health worker (CHW) support to standard care. Methods: The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) trial is an ongoing multicenter, 3-arm, open-label randomized controlled trial; 375 emerging adults (aged 17-25 years) are being enrolled and randomized 1:1:1 to (1) a 6-month CHW intervention focused on self-management skills, symptom tracking, care coordination, and transition planning; (2) a 6-month mHealth self-management program (enhanced iManage application) with tailored SMS text messaging (THRIVE [Texting Health-Related Resources to Inform, Motivate, and Engage] 2.0); or (3) enhanced usual care (control). Participants are followed for 18 months. The primary outcome is the change in self-reported health-related quality of life assessed using the PedsQL SCD module. Secondary outcomes include acute care use (hospitalizations and emergency department visits), patient activation, self-management behavior, and successful transfer to adult hematology care. Results: The institutional review board at Children’s Hospital of Philadelphia approved this study in June 2018. Recruitment began in January 2019 and ended in December 2022; we completed data collection in November 2024. We have enrolled a total of 405 participants. Conclusions: This trial addresses a critical gap in transition intervention research for young adults with SCD. It will provide evidence on the comparative effectiveness of 2 promising interventions (CHW and mHealth) and inform the development of scalable and sustainable transition support programs. Findings will have implications for improving health-related quality of life, reducing acute care use, and promoting successful transition to adult-centered SCD care for this vulnerable population. Trial Registration: ClinicalTrials.gov NCT03648710; https://clinicaltrials.gov/study/NCT03648710 International Registered Report Identifier (IRRID): DERR1-10.2196/69239


  • International variations in body mass index within the CASiRe global cohort of sickle cell disease patients

    by Crawford Strunk, Angela Rivers, Catherine Segbefia, Raffaella Colombatti, Immacolata Tartaglione, Deepa Manwani, Eugenia Vicky Asare, Connie M Piccone, Donna Boruchov, William T Zempsky, et al.

    Objectives: Although SCD has traditionally been associated with underweight status, body mass index (BMI) status is shifting globally. As disease-modifying therapies have become available, BMI status has increased. Our aim was to determine the prevalence and risk factors of underweight, overweight, and obese statuses in SCD patients in low-middle and high-income countries. Methods: The CASiRe research consortium cross-sectionally analyzed the association of BMI status (underweight, normal weight, overweight, and obesity) to age, genotype, treatment status, and associated clinical outcomes of 532 SCD patients from Italy, United States, and Ghana. Results: Overall, BMI status varied significantly between countries (underweight P < .001, obesity P < .001, overweight P = .038). Underweight (9.5%-17.2%) and overweight/obesity (14%-27.8%) statuses increased from pediatrics to adults. Hemoglobin (Hgb) SC represented the highest percentage of overweight/obese patients (Hgb SC 49% vs SS/SB0Thal 16%, P < .001). Hydroxyurea use (HgbSS/SB0Thal [-]Hydroxyurea 11% vs [+]Hydroxyurea 32% overweight/obese, P < .001), higher hemoglobin levels (Adults, R = 0.396 P < .001), and genotype (HgbSS/SB0Thal vs SC, P < .001) correlated with overweight/obesity status. Lower hemoglobin (OR 0.77, P < .001) and male sex (OR 0.41 P < .001) were predictors of underweight status while higher hemoglobin (OR 1.38, P < .001) and older age (OR 1.01, P = .031) were predictors of obesity. Underweight status was associated with Ghanian site, male gender, leg ulcers, and microalbuminuria showing that it remains a significant clinical issue. Conclusions: As access to disease-modifying therapy improves for SCD, monitoring for overweight and obesity and their comorbid conditions may be necessary. Underweight SCD patients should be carefully evaluated for end-organ complications, especially in low-resource settings.


  • Open Access

    The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) Trial: Protocol for a Randomized Controlled Trial (Preprint)

    by Tanisha D Belton, Caren M Steinway, Olivia Teng, Justine Shults, Lamia P Barakat, Banu Aygun, Abena Appiah-Kubi, Lori E Crosby, Omar Niss, Biree Andemariam, et al.

    BACKGROUND Transitioning from pediatric to adult sickle cell disease (SCD) care is challenging for emerging adults (aged 17-25 years). This period is marked by a 7-fold increase in mortality rates and has the highest rates of hospitalizations, emergency room visits, and hospital readmissions compared with children living with SCD. These challenges are exacerbated by fragmented care coordination, difficulty navigating adult health care systems, and increased self-management responsibilities. OBJECTIVE This study aims to compare the effectiveness of 2 interventions designed to support emerging adults living with SCD during this transition: a mobile health (mHealth) app and community health worker (CHW) support to standard care. METHODS The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) trial is an ongoing multicenter, 3-arm, open-label randomized controlled trial; 375 emerging adults (aged 17-25 years) are being enrolled and randomized 1:1:1 to (1) a 6-month CHW intervention focused on self-management skills, symptom tracking, care coordination, and transition planning; (2) a 6-month mHealth self-management program (enhanced iManage application) with tailored SMS text messaging (THRIVE [Texting Health-Related Resources to Inform, Motivate, and Engage] 2.0); or (3) enhanced usual care (control). Participants are followed for 18 months. The primary outcome is the change in self-reported health-related quality of life assessed using the PedsQL SCD module. Secondary outcomes include acute care use (hospitalizations and emergency department visits), patient activation, self-management behavior, and successful transfer to adult hematology care. RESULTS The institutional review board at Children’s Hospital of Philadelphia approved this study in June 2018. Recruitment began in January 2019 and ended in December 2022; we completed data collection in November 2024. We have enrolled a total of 405 participants. CONCLUSIONS This trial addresses a critical gap in transition intervention research for young adults with SCD. It will provide evidence on the comparative effectiveness of 2 promising interventions (CHW and mHealth) and inform the development of scalable and sustainable transition support programs. Findings will have implications for improving health-related quality of life, reducing acute care use, and promoting successful transition to adult-centered SCD care for this vulnerable population. CLINICALTRIAL ClinicalTrials.gov NCT03648710; https://clinicaltrials.gov/study/NCT03648710 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/69239

  • Open Access

    Correction to: Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States

    by Chuka Udeze, Kristin A. Evans, Yoojung Yang, Timothy Lillehaugen, Janna Manjelievskaia, Urvi Mujumdar, Nanxin Li, Biree Andemariam